Biomanufacturing Featured Articles
-
Practical — And Crucial — Actions To Take Now For DSCSA Compliance
6/29/2023
Serialized data exchange, enhanced verification, and tracing, oh my! Many companies are still unprepared for full DSCSA implementation in November. Is your company one of them? Here are the important actions to take now.
-
Do You Know What Your Supply Really Costs?
6/28/2023
Discover some of the questions you can consider to avoid hidden costs when managing your supply chain and mitigating risk for materials used directly in bioproduction.
-
4 Key Considerations For Onshoring Or Nearshoring Of Drug Production
6/28/2023
Is reshoring or nearshoring right for your organization? It's important to undertake rigorous internal assessments to arrive at a decision. Here are four key considerations.
-
Understanding The Hidden Value Of Quality
6/26/2023
Costs of poor quality (COPQ) cannot be overstated. Review the statistics that prove how costly it can be to avoid resolving quality issues in your processes and supply chain.
-
Fit-For-Purpose Lipids Can Accelerate, Scale, And Improve RNA-LNP Drugs
6/22/2023
Emerging biotech companies are investing in novel delivery capabilities to address different modalities' needs and extra-hepatic delivery. Explore steps to accelerate commercial nanomedicine delivery.
-
How LNP Technology Meets The Delivery Need Of saRNA Vaccines
6/22/2023
Explore challenges to the successful development of RNA-based drugs and vaccines as well as the advantages of utilizing lipid nanoparticle technology as a delivery platform for saRNA.
-
Leveraging Single-Use Technology For mRNA-LNP Drug Manufacturing
6/12/2023
Single-use technology is vital for ensuring the quality and expedited market entry of genomic medicines. Learn how LNP technology is paving the way for a new era of personalized, precise medicine.
-
3 Action Items For The US Bio/Pharma Industry To Mitigate Supply Vulnerabilities
6/12/2023
The United States’ reliance on foreign manufacturers of API has been a known fact for several years. We can mitigate our supply vulnerabilities, but bio/pharma companies and the FDA both have roles to fill in this need.
-
Will POC Manufacturing Unlock The Value Of Autologous Cell Therapies?
6/5/2023
To shorten the treatment journey for autologous cell therapy patients, a promising model that appears to be emerging is point-of-care (PoC) manufacturing in major cancer and academic medical centers and hospital networks. PoC has the potential to address other ongoing concerns, such as the reduction of risks and costs.
-
Can Life Sciences Untangle Tech Transfer?
5/19/2023
Explore the complexities of tech transfer, what is slowing tech transfer down on a commercial level, and the two-pathway approach you can take when adopting digital native tools.